Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
| Revenue (TTM) | $959.90M |
| Gross Profit (TTM) | $723.99M |
| EBITDA | $255.99M |
| Operating Margin | 34.20% |
| Return on Equity | 20.50% |
| Return on Assets | 11.60% |
| Revenue/Share (TTM) | $16.63 |
| Book Value | $17.19 |
| Price-to-Book | 2.22 |
| Price-to-Sales (TTM) | 2.31 |
| EV/Revenue | 1.777 |
| EV/EBITDA | 6.09 |
| Quarterly Earnings Growth (YoY) | 88.20% |
| Quarterly Revenue Growth (YoY) | 30.30% |
| Shares Outstanding | $58.24M |
| Float | $52.08M |
| % Insiders | 11.63% |
| % Institutions | 99.36% |
Volatility is currently contracting
Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.
Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.
Stocks like SNX, AMP, HRMY and NWL are seeing price strength and have a high chance of carrying the momentum forward.
PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.
Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline. HRMY management has become even more specific about business development—exactly the kind of thing I thought was missing earlier. My updated valuation suggests most of the improvement is now reflected in the stock. I am, therefore, upgrading HRMY from Sell to Hold.
HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcript
Harmony Biosciences NASDAQ: HRMY reported second-quarter net revenue of $261.3 million, up 30% from the prior-year period and 21% sequentially, as sales of its narcolepsy treatment WAKIX rebounded from seasonal market-access pressures earlier in the year.
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.68 per share a year ago.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HRMY and any ticker you trade — then tracks every position and per-strategy win rate.
